Outcomes of adults with cystic fibrosis infected with antibiotic-resistant Pseudomonas aeruginosa
- PMID: 16113513
- DOI: 10.1159/000087686
Outcomes of adults with cystic fibrosis infected with antibiotic-resistant Pseudomonas aeruginosa
Abstract
Background: Although Pseudomonas aeruginosa is the most common bacterial infection in adults with cystic fibrosis and frequently develops resistance to multiple classes of antibiotics, it has not been determined whether patients with multiple antibiotic-resistant Pseudomonas aeruginosa have worse clinical outcomes than patients with more susceptible strains.
Objectives: This study assessed the impact of multiply-resistant P. aeruginosa on lung function, hospitalizations, antibiotic use, lung transplantation and survival in adults with cystic fibrosis.
Methods: In a cohort study at a university-based adult cystic fibrosis program, 75 consecutive adult cystic fibrosis patients who had P. aeruginosa isolated from sputum cultures were studied over a 4-year period. Outcomes included decline in FEV1, clinic visits, hospitalizations, courses and days of intravenous antibiotics, and lung transplantation. Multiple linear and Poisson regression for repeated measures were used to assess the outcomes.
Results: In comparison to patients with susceptible strains, patients with resistant P. aeruginosa had more severe baseline lung disease, more rapid decline in FEV1 (160 ml/year, p = 0.003) and were significantly more likely to undergo lung transplantation (17.6 vs. 0%, p = 0.005).
Conclusions: Infection with multiple-antibiotic-resistant P. aeruginosa is associated with accelerated progression of cystic fibrosis, and has important implications for infection control strategies, antibiotic use and lung transplantation.
Copyright 2006 S. Karger AG, Basel.
Comment in
-
Pseudomonas aeruginosa and cystic fibrosis--a nasty bug gets nastier.Respiration. 2006;73(1):16-7. doi: 10.1159/000090992. Respiration. 2006. PMID: 16498269 No abstract available.
-
Antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis.Respiration. 2007;74(3):356; author reply 357. doi: 10.1159/000098405. Epub 2007 Jan 5. Respiration. 2007. PMID: 17204830 No abstract available.
Similar articles
-
Poor clinical outcomes associated with a multi-drug resistant clonal strain of Pseudomonas aeruginosa in the Tasmanian cystic fibrosis population.Respirology. 2008 Nov;13(6):886-92. doi: 10.1111/j.1440-1843.2008.01383.x. Respirology. 2008. PMID: 18811887
-
Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response.APMIS Suppl. 2003;(116):1-47. APMIS Suppl. 2003. PMID: 14692154 Review.
-
Infection with transmissible strains of Pseudomonas aeruginosa and clinical outcomes in adults with cystic fibrosis.JAMA. 2010 Nov 17;304(19):2145-53. doi: 10.1001/jama.2010.1665. JAMA. 2010. PMID: 21081727
-
Effect of mutator P. aeruginosa on antibiotic resistance acquisition and respiratory function in cystic fibrosis.Pediatr Pulmonol. 2009 Aug;44(8):820-5. doi: 10.1002/ppul.21076. Pediatr Pulmonol. 2009. PMID: 19598278
-
The approach to Pseudomonas aeruginosa in cystic fibrosis.Semin Respir Crit Care Med. 2009 Oct;30(5):587-95. doi: 10.1055/s-0029-1238917. Epub 2009 Sep 16. Semin Respir Crit Care Med. 2009. PMID: 19760546 Review.
Cited by
-
Molecular epidemiological surveillance of multidrug-resistant Pseudomonas aeruginosa isolates in a pediatric population of patients with cystic fibrosis and determination of risk factors for infection with the Houston-1 strain.J Clin Microbiol. 2013 Apr;51(4):1237-40. doi: 10.1128/JCM.02157-12. Epub 2013 Jan 9. J Clin Microbiol. 2013. PMID: 23303498 Free PMC article.
-
Predictors of pulmonary exacerbations in patients with cystic fibrosis infected with multi-resistant bacteria.Thorax. 2006 Nov;61(11):969-74. doi: 10.1136/thx.2006.061366. Epub 2006 Jul 14. Thorax. 2006. PMID: 16844728 Free PMC article. Clinical Trial.
-
Persistence and Microevolution of Pseudomonas aeruginosa in the Cystic Fibrosis Lung: A Single-Patient Longitudinal Genomic Study.Front Microbiol. 2019 Jan 11;9:3242. doi: 10.3389/fmicb.2018.03242. eCollection 2018. Front Microbiol. 2019. PMID: 30692969 Free PMC article.
-
Effects of green tea compound epigallocatechin-3-gallate against Stenotrophomonas maltophilia infection and biofilm.PLoS One. 2014 Apr 1;9(4):e92876. doi: 10.1371/journal.pone.0092876. eCollection 2014. PLoS One. 2014. PMID: 24690894 Free PMC article.
-
Adaptation and Evolution of Pathogens in the Cystic Fibrosis Lung.J Pediatric Infect Dis Soc. 2022 Sep 7;11(Supplement_2):S23-S31. doi: 10.1093/jpids/piac073. J Pediatric Infect Dis Soc. 2022. PMID: 36069898 Free PMC article. Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical